ID   OV-1369(R2)
AC   CVCL_9T12
SY   OV1369(R2); OV-1369(2)
DR   cancercelllines; CVCL_9T12
DR   CancerTools; 161769
DR   GEO; GSM2474980
DR   Wikidata; Q54936821
RX   PubMed=22931248;
RX   PubMed=28273451;
CC   Doubling time: 2.45 +- 0.12 days (PubMed=22931248).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451).
CC   Omics: Transcriptomics; RNAseq.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson, Anne-Marie.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 11,13
ST   D21S11: 30,31
ST   D5S818: 13
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9T17 ! TOV-1369
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 10-04-25; Version: 14
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379; PMCID=PMC3532154;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//